• br Introduction The vacuolar ATPases V ATPases

  2025-02-26

  

  Introduction The vacuolar ATPases (V-ATPases) are ATP-driven proton pumps that play important roles in both normal and disease processes [1], [2], [3], [4], [5]. V-ATPases within cells function in such processes as intracellular membrane traffic, protein processing and degradation, coupled transp

• The analysis of the profile of protein phosphorylation in

  2025-02-26

  

  The analysis of the profile of protein phosphorylation in MMS-treated Adriamycin HCl confirmed that both the ATM and ATR pathways were activated in S-phase blocked cells. Interestingly, phosphorylation of Chk1 was observed 24h after MMS-treatment both in AT- and ATM-inhibited cells, whilst in the a

• br Experimental procedures br Results br Discussion Major de

  2025-02-26

  

  Experimental procedures Results Discussion Major depressive disorder is among the leading causes of disability worldwide (Vos et al., 2015). One of the major causal or exacerbating factors of depression is long term stress or psychological trauma (Liu and Alloy, 2010). Dysregulation of the

• cdc42 Sustained release property is also associated

  2025-02-25

  

  Sustained release property is also associated with side effects reduction [16] that could be confirmed by histopathological analyzes. Massive infiltrating inflammatory cells, hyperproliferation of skin layers and keratin pearls, caused by DMBA and croton oil application [32] are attenuated in Imq-lo

• br Acknowledgments br Introduction Angiotensin II AngII is

  2025-02-25

  

  Acknowledgments Introduction Angiotensin II (AngII) is among the most potent vasoactive substances produced in humans. Its effects are numerous, from vasoconstriction to control of fluid and electrolytes balances. Many of the physiological and pathological effects of AngII are mediated by the

• Immunohistochemistry in tissue samples showed the expression

  2025-02-25

  

  Immunohistochemistry in tissue samples showed the expression of several nuclear receptor co-activators, including NCOA1, NCOA2, NCOA3, CREBBP, and EP300, in 85–100% of ion channels tumors even some of which lacked AR expression (Boorjian et al., 2009). Knockdown of each co-activator also resulted i

• br Role of AMPK in inflammation signaling Pro

  2025-02-25

  

  Role of AMPK in inflammation signaling Pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α), activate Ikβ kinase (IKKβ), which phosphorylates IκBα, triggering the degradation of proteasomal IκB. This liberates active nuclear factor kB (NF-kB) to translocate i

• br Material and methods br Results br Discussion Aminopeptid

  2025-02-25

  

  Material and methods Results Discussion Aminopeptidase N is a transmembrane protease present in a wide variety of human tissues and cell types (endothelial, epithelial, fibroblast, leukocyte). APN expression is dysregulated in inflammatory diseases as well as in solid and hematologic tumors

• br Materials and methods br Results br Discussion We

  2025-02-25

  

  Materials and methods Results Discussion We have in this study used semi-nested degenerative PCR to identify the lipoxygenases expressed in the lung tissue from M. fascicularis and report on the identification of 5- and 12/15-LO transcripts from this tissue. Although we did not find transcr

• Gemcitabine Lorlatinib is an orally active brain penetrant c

  2025-02-25

  

  Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F

• The G R mutation is located

  2025-02-25

  

  The G1202R mutation is located at the solvent front of the ALK kinase domain adjacent to the inhibitor's binding pocket. Although barely reported in the setting of crizotinib resistance, it has emerged as the most refractory mutation to both the first- and second-generation ALK inhibitors. The large

• In large biopsies series from ALK NSCLC treated

  2025-02-25

  

  In large biopsies series from ALK+ NSCLC treated patients, the number of detected mutations increased after second generation ALKi (Gainor et al., 2016) and in one study were present in 56% of the entire cohort (Shaw et al., 2013b). For example, the rate of G1202R mutations increases from 2% in post

• Similar to V the temporal neocortex of mammals including

  2025-02-25

  

  Similar to V1, the temporal neocortex of mammals, including the primary auditory cortex (A1), is densely innervated by 5-HT fibers originating mainly in the dorsal raphe nucleus (Campbell et al., 1987, Harding and Paxinos, 2004, Törk, 1990), and the major atomoxetine hcl of 5-HTRs are expressed thro

• br Perspectives and challenges Previously the main

  2025-02-25

  

  Perspectives and challenges Previously, the main focus of development of adenosine targets for pain was on A1Rs, due to prominent antinociception in multiple preclinical models and preliminary observations in human trials. However, delivery of agonists can be limited by other (e.g. cardiovascular

• We further analyzed selected hit

  2025-02-25

  

  We further analyzed selected hit compounds for their ability to inhibit human AdK in intact cells. Human 1321N1 astrocytoma Agarose GPG/LMP low melt were utilized which were found to express AdK. The whole cell assay was performed using a 96-well format. The standard AdK inhibitor 5-iodotubercidin

16076 records 22/1072 page Previous Next First page 上5页 2122232425 下5页 Last page